Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Apple Turns 50: From Garage Startup to AI Crossroads 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
WALTHAM, Mass., Sept. 05, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that company management will participate in the following investor conferences:
- Morgan Stanley Annual Global Health Care Conference
Monday, September 11, 2017 at 3:40 p.m. ET
Location: New York, NY - Cantor Fitzgerald Global Healthcare Conference
Wednesday, September 27, 2017 at 2:50 p.m. ET
Location: New York, NY - Deutsche Bank Leveraged Finance Conference
Wednesday, October 4, 2017 at 3:35 p.m. MT (6:35 p.m. ET)
Location: Scottsdale, AZ
To access the live webcasts, please visit the Investors section of the company’s website at www.amagpharma.com. A replay of each event will be archived on the site for 30 days.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women’s health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. CBR® is a registered trademark of Cbr Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638
